Pacific Biosciences of California (MEX:PACB) EBIT: MXN-2,221 Mil (TTM As of Mar. 2026)


MEX:PACB Pacific Biosciences of California Inc MEX:PACB
53 GF Score
Price MXN27.50
GF Value MXN27.00
! 8 Warning Signs
View Full Analysis

What is Pacific Biosciences of California EBIT?

Pacific Biosciences of California MEX:PACB 53 EBIT is MXN-2,221 Mil as of Mar. 2026. GuruFocus rates MEX:PACB with a GF Score™ of 53/100 and a GF Value™ of MXN27.00. The stock has 8 warning signs investors should review.

Pacific Biosciences of California's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-115 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-2,221 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pacific Biosciences of California's annualized ROC % for the quarter that ended in Mar. 2026 was -47.69%. Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -27.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pacific Biosciences of California's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13.12%.

Pacific Biosciences of California  (MEX:PACB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pacific Biosciences of California's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3906.1 * ( 1 - 0% )/( (8105.464 + 8275.025)/ 2 )
=-3906.1/8190.2445
=-47.69 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14117.963 - 979.798 - ( 5032.701 - max(0, 1311.373 - 6753.074+5032.701))
=8105.464

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14108.153 - 856.788 - ( 4976.34 - max(0, 1178.527 - 6663.389+4976.34))
=8275.025

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-458.104/( ( (1185.513 + max(417.067, 0)) + (1176.129 + max(513.517, 0)) )/ 2 )
=-458.104/( ( 1602.58 + 1689.646 )/ 2 )
=-458.104/1646.113
=-27.83 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(638.266 + 887.411 + 194.696) - (979.798 + 286.939 + 36.569)
=417.067

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(529.26 + 920.064 + 237.725) - (856.788 + 294.474 + 22.27)
=513.517

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pacific Biosciences of California's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-2220.744/16929.055
=-13.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California EBIT Related Terms

Pacific Biosciences of California EBIT Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California EBIT Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,381.68 -5,840.18 -5,157.05 -6,175.85 -9,706.95

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,687.37 -756.12 -658.15 -691.94 -114.53

MEX:PACB vs KIDS, MOBI, SI: EBIT Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's EV-to-EBIT falls into.


MEX:PACB
53GF Score
Pacific Biosciences of California Inc MEX:PACB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,221 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-2,221 Mil mean?
Pacific Biosciences of California (MEX:PACB) has a EBIT of MXN-2,221 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pacific Biosciences of California.
Is Pacific Biosciences of California's EBIT too high?
Pacific Biosciences of California's current EBIT is MXN-2,221 Mil. Overall, Pacific Biosciences of California has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's EBIT compare to KIDS and MOBI?
Pacific Biosciences of California's EBIT of MXN-2,221 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pacific Biosciences of California. Pacific Biosciences of California's current EBIT is MXN-2,221 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Pacific Biosciences of California (MEX:PACB) has a current EBIT of MXN-2,221 Mil. The stock's GF Value™ is MXN27.00, compared to a current price of MXN27.50 — trading 1.9% above its estimated fair value. The current EBIT is MXN-2,221 Mil. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pacific Biosciences of California (MEX:PACB), the current EBIT is MXN-2,221 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (MEX:PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued. The current stock price of MXN27.50 is trading 1.9% above its estimated GF Value™ of MXN27.00.

Key valuation signals for MEX:PACB:

  • EBIT: MXN-2,221 Mil
  • GF Value™: MXN27.00 vs. price of MXN27.50 (1.9% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the MEX:PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges PACB:USAP09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score

Get the complete analysis for MEX:PACB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN27.50
Price
MXN27.00
GF Value